1. Name Of The Medicinal Product
Keppra 250 mg film-coated tablets.
Keppra 500 mg film-coated tablets.
Keppra 750 mg film-coated tablets.
Keppra 1000 mg film-coated tablets.
Keppra 100 mg/ml, oral solution.
Keppra 100 mg/ml concentrate for solution for infusion
2. Qualitative And Quantitative Composition
Tablets:
Each film-coated tablet contains 250 mg levetiracetam, 500 mg levetiracetam, 750 mg levetiracetam or 1000 mg levetiracetam.
Excipient:
Keppra 750 mg film-coated Tablets:
Each film-coated tablet contains 0.19 mg of sunset yellow FCF (E110).
Oral solution:
Each ml contains 100 mg levetiracetam.
Excipients: methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216) and 300 mg maltitol liquid.
Solution for infusion:
Each ml contains 100 mg of levetiracetam.
Each 5 ml vial contains 500 mg of levetiracetam.
Excipients:
Each dose contains 57 mg of sodium.
For a full list of excipients, see section 6.1.
3. Pharmaceutical Form
Film-coated tablet:
Blue, oblong, scored and debossed with the code “ucb” and “250” on one side.
Yellow, oblong, scored and debossed with the code “ucb 500” on one side.
Orange, oblong, scored and debossed with the code “ucb 750” on one side.
White, oblong, scored and debossed with the code “ucb 1000” on one side.
Oral solution:
Clear liquid.
Concentrate for solution for infusion (sterile concentrate).
Clear, colourless, concentrate.
4. Clinical Particulars
4.1 Therapeutic Indications
Keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
Keppra is indicated as adjunctive therapy
• in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 1 month of age with epilepsy.
• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Keppra concentrate is an alternative for patients (adults and children from 4 years of age) when oral administration is temporarily not feasible.
4.2 Posology And Method Of Administration
Posology
Monotherapy for adults and adolescents from 16 years of age
The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily.
Add-on therapy for adults (
The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment.
Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks.
Duration of treatment
There is no experience with administration of intravenous levetiracetam for longer period than 4 days.
Special populations
Elderly (65 years and older)
Adjustment of the dose is recommended in elderly patients with compromised renal function (see “Renal impairment” below).
Renal impairment
The daily dose must be individualised according to renal function.
For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in ml/min is needed. The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighting 50 kg or more, the following formula:
Then CLcr is adjusted for body surface area (BSA) as follows:
Dosing adjustment for adult and adolescents patients weighing more than 50 kg with impaired renal function:
Group
|
Creatinine clearance (ml/min/1.73m2)
|
Dose and frequency
|
Normal
Mild
Moderate
Severe
End-stage renal disease patients undergoing dialysis (1)
|
> 80
50-79
30-49
< 30
-
|
500 to 1,500 mg twice daily
500 to 1,000 mg twice daily
250 to 750 mg twice daily
250 to 500 mg twice daily
500 to 1,000 mg once daily (2)
|
(1) A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.
(2) Following dialysis, a 250 to 500 mg supplemental dose is recommended.
For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. This recommendation is based on a study in adult renally impaired patients.
The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination using, for young adolescents and children using the following formula (Schwartz formula):
ks= 0.45 in Term infants to 1 year old; ks= 0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in adolescent male
Dosing adjustment for infants, children and adolescents patients weighing less than 50 kg with impaired renal function:
Group
|
Creatinine clearance (ml/min/1.73 m2)
|
Dose and frequency (1)
|
|
Infants 1 to less than 6 months
|
Infants 6 to 23 months, children and adolescents weighing less than 50 kg
|
|
|
Normal
|
> 80
|
7 to 21 mg/kg (0.07 to 0.21 ml/kg) twice daily
|
10 to 30 mg/kg (0.10 to 0.30 ml/kg) twice daily
|
Mild
|
50-79
|
7 to 14 mg/kg (0.07 to 0.14 ml/kg) twice daily
|
10 to 20 mg/kg (0.10 to 0.20 ml/kg) twice daily
|
Moderate
|
30-49
|
3.5 to 10.5 mg/kg (0.035 to 0.105 ml/kg) twice daily
|
5 to 15 mg/kg (0.05 to 0.15 ml/kg) twice daily
|
Severe
|
< 30
|
3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) twice daily
|
5 to 10 mg/kg (0.05 to 0.10 ml/kg) twice daily
|
End-stage renal disease patients undergoing dialysis
|
--
|
7 to 14 mg/kg (0.07 to 0.14 ml/kg) once daily (2) (4)
|
10 to 20 mg/kg (0.10 to 0.20 ml/kg) once daily (3) (5)
|
(1) Keppra oral solution should be used for doses under 250 mg and for patients unable to swallow tablets.
(2) A 10.5 mg/kg (0.105 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.
(3) A 15 mg/kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.
(4) Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended.
(5) Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.
Hepatic impairment
No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. Therefore a 50 % reduction of the daily maintenance dose is recommended when the creatinine clearance is < 60 ml/min/1.73 m2.
Paediatric population
The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose.
The tablet formulation is not adapted for use in infants and children under the age of 6 years. Keppra oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases Keppra oral solution should be used.
The safety and efficacy of Keppra concentrate for solution for infusion in infants and children less than 4 years have not been established.
Monotherapy
The safety and efficacy of Keppra in children and adolescents below 16 years as monotherapy treatment have not been established.
There are no data available.
Add-on therapy for children aged 4 to 11 years and adolescents (12 to 17 years) weighing less than 50 kg
Keppra oral solution is the preferred formulation for use in infants and children under the age of 6 years.
The initial therapeutic dose is 10 mg/kg twice daily.
Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used.
Dose in children 50 kg or greater is the same as in adults.
Dose recommendations for infants from 6 months of age, children and adolescents:
Weight
|
Starting dose:
10 mg/kg twice daily
|
Maximum dose:
30 mg/kg twice daily
|
6 kg (1)
|
60 mg (0.6 ml) twice daily
|
180 mg (1.8 ml) twice daily
|
10 kg (1)
|
100 mg (1 ml) twice daily
|
300 mg (3 ml) twice daily
|
15 kg (1)
|
150 mg (1.5 ml) twice daily
|
450 mg (4.5 ml) twice daily
|
20 kg (1)
|
200 mg (2 ml) twice daily
|
600 mg (6 ml) twice daily
|
25 kg
|
250 mg twice daily
|
750 mg twice daily
|
From 50 kg (2)
|
500 mg twice daily
|
1,500 mg twice daily
|
(1) Children 25 kg or less should preferably start the treatment with Keppra 100 mg/ml oral solution.
(2) Dose in children and adolescents 50 kg or more is the same as in adults.
Add-on therapy for infants aged from 1 month to less than 6 month.
The oral solution is the formulation to use in infants.
The initial therapeutic dose is 7 mg/kg twice daily.
Depending upon the clinical response and tolerability, the dose can be increased up to 21 mg/kg twice daily. Dose changes should not exceed increases or decreases of 7 mg/kg twice daily every two weeks. The lowest effective dose should be used.
Infants should start the treatment with Keppra 100 mg/ml oral solution.
Dose recommendations for infants aged from 1 month to less than 6 months:
Weight
|
Starting dose:
7 mg/kg twice daily
|
Maximum dose:
21 mg/kg twice daily
|
4 kg
|
28 mg (0.3 ml) twice daily
|
84 mg (0.85 ml) twice daily
|
5 kg
|
35 mg (0.35 ml) twice daily
|
105 mg (1.05 ml) twice daily
|
7 kg
|
49 mg (0.5 ml)twice daily
|
147 mg (1.5 ml) twice daily
|
Three presentations are available:
- A 300 ml bottle with a 10 ml oral syringe (containing up to 1000 mg levetiracetam) graduated every 0.25 ml (corresponding to 25 mg).
This presentation should be prescribed for children aged 4 years and older, adolescents and adults.
- A 150 ml bottle with a 3 ml oral syringe (containing up to 300 mg levetiracetam) graduated every 0.1 ml (corresponding to 10 mg)
In order to ensure the accuracy of the dosing, this presentation should be prescribed for infants and young children aged from 6 months to less than 4 years.
- A 150 ml bottle with a 1 ml oral syringe (containing up to 100 mg levetiracetam) graduated every 0.05 ml (corresponding to 5 mg)
In order to ensure the accuracy of the dosing, this presentation should be prescribed for infants aged 1 month to less than 6 months.
Method of administration - tablets
The film-coated tablets must be taken orally, swallowed with a sufficient quantity of liquid and may be taken with or without food. The daily dose is administered in two equally divided doses.
Method of administration
The oral solution may be diluted in a glass of water or baby's bottle and may be taken with or without food. A graduated oral syringe, an adaptor for the syringe and instructions for use in the package leaflet are provided with Keppra.
The daily dose is administered in two equally divided doses.
Method of administration – solution for infusion
Keppra therapy can be initiated with either intravenous or oral administration.
Conversion to or from oral to intravenous administration can be done directly without titration. The total daily dose and frequency of administration should be maintained.
Keppra concentrate is for intravenous use only and the recommended dose must be diluted in at least 100 ml of a compatible diluent and administered intravenously as a 15-minute intravenous infusion (see section 6.6).
4.3 Contraindications
Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients.
4.4 Special Warnings And Precautions For Use
Discontinuation
In accordance with current clinical practice, if Keppra has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks).
Renal insufficiency
The administration of Keppra to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2).
Suicide
Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known.
Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.
Paediatric population
The tablet formulation is not adapted for use in infants and children under the age of 6 years.
Available data in children did not suggest impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.
The safety and efficacy of levetiracetam has not been thoroughly assessed in infants with epilepsy aged less than 1 year. Only 35 infants aged less than 1 year with partial onset seizures have been exposed in clinical studies of which only 13 were aged < 6 months.
Excipients - tablets
Keppra 750 mg film-coated tablets contain E110 colouring agent which may cause allergic reactions.
Excipients – oral solution
Keppra 100 mg/ml oral solution includes methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed).
It also includes maltitol liquid; patients with rare hereditary problems of fructose intolerance should not take this medicinal product.
Excipients – solution for infusion
This medicinal product contains 2.5 mmol (or 57 mg) sodium per maximum single dose. To be taken into consideration by patients on a controlled sodium diet.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
Antiepileptic medicinal products
Pre-marketing data from clinical studies conducted in adults indicate that Keppra did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of Keppra.
As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam.
A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. However, data suggested a 20 % higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. Dose adjustment is not required.
Probenecid
Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low. It is expected that other medicinal products excreted by active tubular secretion could also reduce the renal clearance of the metabolite. The effect of levetiracetam on probenecid was not studied and the effect of levetiracetam on other actively secreted medicinal products, e.g. NSAIDs, sulfonamides and methotrexate, is unknown.
Oral contraceptives and other pharmacokinetics interactions
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.
Antacids
No data on the influence of antacids on the absorption of levetiracetam are available.
Food and alcohol
The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced.
No data on the interaction of levetiracetam with alcohol are available.
4.6 Pregnancy And Lactation
Pregnancy
There are no adequate data available from the use of levetiracetam in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for human is unknown.
Keppra is not recommended during pregnancy and in women of childbearing potential not using contraception unless clearly necessary.
As with other antiepileptic medicinal products, physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy). Appropriate clinical management of pregnant women treated with levetiracetam should be ensured. Discontinuation of antiepileptic treatments may result in exacerbation of the disease which could be harmful to the mother and the foetus.
Breastfeeding
Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended.
However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding.
Fertility
No impact on fertility was detected in animal studies (see section 5.3). No clinical data are available, potential risk for human is unknown.
4.7 Effects On Ability To Drive And Use Machines
No studies on the effects on the ability to drive and use machines have been performed.
Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks, e.g. driving vehicles or operating machinery. Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected.
4.8 Undesirable Effects
Summary of the safety profile
The adverse event profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam. These data are supplemented with the use of levetiracetam in corresponding open-label extension studies, as well as post-marketing experience. The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness. The safety profile of levetiracetam is generally similar across age groups (adult and paediatric patients) and across the approved epilepsy indications.
Tabulated list of adverse reactions
Adverse reactions reported in clinical studies (adults, adolescents, children and infants > 1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency. The frequency is defined as follows: very common (
MedDRA SOC
|
Frequency category
|
|
|
|
Very common
|
Common
|
Uncommon
|
Rare
|
|
Infections and infestations
|
Nasopharyngitis
|
|
|
Infection
|
Blood and lymphatic system disorders
|
|
|
Thrombocytopenia, leukopenia(1)
|
Pancytopenia (1,2), neutropenia(1)
|
Metabolism and nutrition disorders
|
|
Anorexia
|
Weight decreased (1), weight increase
|
|
Psychiatric disorders
|
|
Depression, hostility/ aggression, anxiety(1), insomnia, nervousness/irritability
|
Suicide attempt(1), suicidal ideation(1), psychotic disorder(1), abnormal behaviour(1), hallucination(1), anger(1), confusional state (1), affect lability/mood swings, agitation
|
Completed suicide(1), personality disorder, thinking abnormal
|
Nervous system disorders
|
Somnolence, headache
|
Convulsion, balance disorder, dizziness, lethargy, tremor
|
Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia(1), disturbance in attention
|
Choreoathetosis(1), dyskinesia(1), hyperkinesia
|
Eye disorders
|
|
|
Diplopia, vision blurred
|
|
Ear and labyrinth disorders
|
|
Vertigo
|
|
|
Respiratory, thoracic and mediastinal disorders
|
|
Cough
|
|
|
Gastrointestinal disorders
|
|
Abdominal pain, diarrhoea, dyspepsia, vomiting, nausea
|
|
Pancreatitis(1)
|
Hepatobiliary disorders
|
|
|
Liver function test abnormal(1)
|
Hepatic failure(1), hepatitis(1)
|
Skin and subcutaneous tissue disorders
|
|
Rash
|
Alopecia(1), eczema, pruitus,
|
Toxic epidermal necrolysis(1), Stevens-Johnson syndrome(1), erythema multiforme(1)
|
Musculoskeletal and connective tissue disorders
|
|
|
Muscular weakness, myalgia
|
|
General disorders and administration site conditions
|
|
Asthenia/fatigue
|
|
|
Injury, poisoning and procedural complications
|
|
|
Injury
|
|
(1) Adverse reactions added during post marketing experience.
(2) Bone marrow suppression identified in some of the cases.
|
|
|
|
|
Description of selected adverse reactions
The risk of anorexia is higher when topiramate is coadministered with levetiracetam.
In several cases of alopecia, recovery was observed when levetiracetam was discontinued.
Paediatric population
In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. Sixty (60) of these patients were treated with levetiracetam in placebo-controlled studies. In patients aged 4-16 years, a total of 645 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. 233 of these patients were treated with levetiracetam in placebo-controlled studies. In both these paediatric age ranges, these data are supplemented with the post-marketing experience of the use of levetiracetam.
The adverse event profile of levetiracetam is generally similar across age groups and across the approved epilepsy indications. Safety results in paediatric patients in placebo-controlled clinical studies were consistent with the safety profile of levetiracetam in adults except for behavioural and psychiatric adverse reactions which were more common in children than in adults. In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile. In infants and children aged 1 month to less than 4 years, irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more frequently than in other age groups or in the overall safety profile.
A double-blind, placebo-controlled paediatric safety study with a non-inferiority design has assessed the cognitive and neuropsychological effects of Keppra in children 4 to 16 years of age with partial onset seizures. It was concluded that Keppra was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population. Results related to behavioural and emotional functioning indicated a worsening in Keppra treated patients on aggressive behaviour as measured in a standardised and systematic way using a validated instrument (CBCL – Achenbach Child Behavior Checklist). However subjects, who took Keppra in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behaviour were not worse than baseline.
4.9 Overdose
Symptoms
Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with Keppra overdoses.
Management of overdose
After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis. There is no specific antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60 % for levetiracetam and 74 % for the primary metabolite.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14.
The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.
Mechanism of action
The mechanism of action of levetiracetam still remains to be fully elucidated but appears to be different from the mechanisms of current antiepileptic medicinal products. In vitro and in vivo experiments suggest that levetiracetam does not alter basic cell characteristics and normal neurotransmission.
In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores. In addition, it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β-carbolines. Furthermore, levetiracetam has been shown in in vitro studies to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related analogues show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.
Pharmacodynamic effects
Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect. The primary metabolite is inactive.
In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge/photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam.
Clinical efficacy and safety
Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy.
In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1000 mg, 2000 mg, or 3000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks. In a pooled analysis, the percentage of patients who achieved 50 % or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7 %, 31.6 % and 41.3 % for patients on 1000, 2000 or 3000 mg levetiracetam respectively and of 12.6 % for patients on placebo.
Paediatric population
In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks. In this study, the patients received levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing).
44.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo had a 50 % or greater reduction from baseline in the partial onset seizure frequency per week. With continued long-term treatment, 11.4 % of the patients were seizure-free for at least 6 months and 7.2 % were seizure-free for at least 1 year.
In paediatric patients (1 month to less than 4 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 116 patients and had a treatment duration of 5 days. In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six months and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 months to less than 4 years old, was use in this study. The total daily dose was administered b.i.d.
The primary measure of effectiveness was the responder rate (percent of patients with
Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial seizures or with generalized tonic-clonic seizures only. The patients were randomized to carbamazepine CR 400 – 1200 mg/day or levetiracetam 1000 – 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Six-month seizure freedom was achieved in 73.0 % of levetiracetam-treated patients and 72.8 % of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95 % CI: -7.8 8.2). More than half of the subjects remained seizure free for 12 months (56.6 % and 58.5 % of subjects on levetiracetam and on carbamazepine CR respectively).
In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69).
